Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Javier Gonzalez
Observed name:
J. Gonzalez
Institutions:
National Institutes of Health,
National Cancer Institute
Observed institutions:
National Institutes of Health,
The Ohio State University Wexner Medical Center,
National Cancer Institute,
The Ohio State University,
The University of Texas Medical Branch at Galveston
ORCID:
0000-0003-2060-7902
Observed ORCID:
0000-0003-2060-7902
OpenAlex ID:
A5047308475
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2 -mutant Glioma
2023
·
Kristina Fanucci
, Mary Jo Pilat
, et al.
·
Cancer Research Communications
·
41
PDF
Combination therapy for malignant glioma based on PTEN status
2008
·
Javier Gonzalez
, John de Groot
·
Expert Review of Anticancer Therapy
·
19
Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.
2022
·
Kristina Fanucci
, Mary Josephine Paula Pilat
, et al.
·
Journal of Clinical Oncology
·
7
Enfermedad de Behcet: presentación de un caso
2014
·
Rafael Victor Pila Pérez
, Rafael Ulises Pila Peláez
, et al.
·
Revista Archivo Médico de Camagüey
·
6
PDF
High-dose methotrexate-based regimens with or without vincristine for the treatment of primary central nervous system lymphoma
2020
·
Tracelyn Freeman
, Carlo S Legasto
, et al.
·
Neuro-Oncology Advances
·
3
PDF
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial
2026
·
Byram H. Ozer
, Scott M. Lindhorst
, et al.
·
medRxiv
·
1
PDF
Supplementary Data from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
2023
·
Kristina Fanucci
, Mary Jo Pilat
, et al.
Supplementary Table 1 from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
2023
·
Kristina Fanucci
, Mary Jo Pilat
, et al.
Data from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
2023
·
Kristina Fanucci
, Mary Jo Pilat
, et al.
Data from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
2023
·
Kristina Fanucci
, Mary Jo Pilat
, et al.
PDF
Rare-23. High Dose Methotrexate With or Without Vincristine for Primary Cns Lymphoma, the Ohio State University Experience
2019
·
Tracelyn Freeman
, Carlo Legasto
, et al.
·
Neuro-Oncology
Phase I Study of Trametinib in Combination with Whole-Brain Radiation Therapy for Brain Metastases
2019
·
D. Fabian
, E.J. Wuthrick
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
Diabetes insípida causada por metástasis hipofisaria de cáncer de mama
2018
·
Rafael Pila Pérez
, F. Martínez
, et al.
·
Revista cubana de neurología y neurocirugía
Erdheim-Chester Disease in the Brainstem Mimicking Tumefactive Demyelination. (P2.381)
2018
·
Maria del Pilar Guillermo Prieto Eibl
, Javier Gonzalez
·
Neurology
Steroid-responsive Dementia with Immunotherapy for Metastatic Melanoma (P6.133)
2018
·
Javier Gonzalez
·
Neurology
Show more works
View as search
Works count:
15
Citation count:
77
H-index:
4
I10-index:
2
Year
Topic
Type